Novartis AG (NOVN) Given Average Recommendation of “Hold” by Analysts

Novartis AG (VTX:NOVN) has been assigned a consensus recommendation of “Hold” from the sixteen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is CHF 88.88.

Several analysts have issued reports on NOVN shares. Morgan Stanley set a CHF 92 price objective on Novartis and gave the company a “buy” rating in a research note on Friday, December 1st. JPMorgan Chase & Co. set a CHF 84 price objective on Novartis and gave the company a “neutral” rating in a research note on Friday, December 29th. Barclays set a CHF 80 price objective on Novartis and gave the company a “sell” rating in a research note on Thursday, January 25th. Credit Suisse Group set a CHF 77 price objective on Novartis and gave the company a “neutral” rating in a research note on Wednesday, January 24th. Finally, Jefferies Group set a CHF 95 price objective on Novartis and gave the company a “buy” rating in a research note on Monday, February 26th.

How to Become a New Pot Stock Millionaire

Novartis stock opened at CHF 78.38 on Friday. Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30. The company has a market capitalization of $206,540.00 and a PE ratio of 25.12.

ILLEGAL ACTIVITY WARNING: “Novartis AG (NOVN) Given Average Recommendation of “Hold” by Analysts” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3298086/novartis-ag-novn-given-average-recommendation-of-hold-by-analysts.html.

About Novartis

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Natus Medical  Releases Quarterly  Earnings Results
Natus Medical Releases Quarterly Earnings Results
FLIR Systems  Announces  Earnings Results
FLIR Systems Announces Earnings Results
Tribune Media  versus Nexstar Media Group  Head to Head Contrast
Tribune Media versus Nexstar Media Group Head to Head Contrast
Rhino Resource Partners  versus Contura Energy  Financial Review
Rhino Resource Partners versus Contura Energy Financial Review
Contrasting Textainer Group  & Its Competitors
Contrasting Textainer Group & Its Competitors
Brokerages Anticipate Interpace Diagnostics Gr  to Announce  EPS
Brokerages Anticipate Interpace Diagnostics Gr to Announce EPS


© 2006-2018 Ticker Report. Google+.